Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EKTERLY | KalVista Pharmaceuticals | N-219301 RX | 2025-07-03 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
ekterly | New Drug Application | 2025-07-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hereditary angioedemas | EFO_0004131 | D054179 | — |
Expiration | Code | ||
---|---|---|---|
SEBETRALSTAT, EKTERLY, KALVISTA | |||
2030-07-03 | NCE | ||
2030-07-03 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Sebetralstat, Ekterly, Kalvista | |||
11234939 | 2039-01-26 | DP | U-4223 |
11230537 | 2037-12-25 | DS, DP | |
11739068 | 2037-06-23 | U-4223 | |
10364238 | 2035-11-26 | DS, DP | |
10611758 | 2035-11-26 | U-4223 | |
11001578 | 2035-11-26 | DS, DP | |
11084809 | 2035-11-26 | DS, DP | U-4223 |
11198691 | 2035-11-26 | U-4223 | |
11234939 | 2039-01-26 | DP | U-4223 |
11230537 | 2037-12-25 | DS, DP | |
11739068 | 2037-06-23 | U-4223 | |
10364238 | 2035-11-26 | DS, DP | |
10611758 | 2035-11-26 | U-4223 | |
11001578 | 2035-11-26 | DS, DP | |
11084809 | 2035-11-26 | DS, DP | U-4223 |
11198691 | 2035-11-26 | U-4223 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hereditary angioedemas | D054179 | EFO_0004131 | — | 1 | 1 | 4 | — | 1 | 7 |
Angioedema | D000799 | EFO_0005532 | T78.3 | 1 | 1 | 3 | — | 1 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hereditary angioedema types i and ii | D056829 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Sebetralstat |
INN | sebetralstat |
Description | Sebetralstat is an oral on-demand therapy to treat acute hereditary angioedema (HAE) attacks. It is designed to reduce the severity and duration of HAE attacks by inhibiting plasma kallikrein, an enzyme that plays a key role in swelling during HAE attacks. Sebetralstat is marketed under the brand name EKTERLY and was approved by the U.S. Food and Drug Administration (FDA) in July 2025 for use in adults and children aged 12 years of age and older. It represents the first orally administered treatment option for acute HAE attacks.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: 1) kallikrein inhibitors or 2) serine protease inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F |
PDB | — |
CAS-ID | 1933514-13-6 |
RxCUI | — |
ChEMBL ID | CHEMBL5095248 |
ChEBI ID | — |
PubChem CID | 121365142 |
DrugBank | DB18305 |
UNII ID | O5ZD2TU2B7 (ChemIDplus, GSRS) |